Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 02 Mar 2023
In people with type 1 diabetes, the immune system attacks and destroys insulin. The cells that control blood sugar and are part of the cells of the pancreas are called islets. Looking for...
Read Full NewsThe history of lobotomy shows the risks for limited evidence and oversight, while modern approaches emphasize targeted treatment, informed consent, and rigorous evaluation.
US radiologists vary substantially in their reading of low-dose CT lung cancer screens, highlighting a need for measures to help standardize interpretation.
Researchers compare first-line chemotherapy regimens in older patients with classical Hodgkin lymphoma to assess whether AVD is associated with better outcomes in routine care.
Researchers analyze individual patient data from five randomized phase 3 trials comparing PORT alone vs PORT plus hormone therapy in patients with recurrent prostate cancer.
A new real-world analysis helps clarify the most informative prognostic PSA benchmark in men with metastatic castration-sensitive prostate cancer.
Tissue-free ctDNA may be comparable to tumor-informed assays in detecting molecular residual disease.
1.
Is There a Role for Stimulants in Beating Cancer Fatigue?
2.
recognizing the mechanism by which the replication of the host cell is outperformed by the skin cancer virus.
3.
Combination treatment may help cut lifelong ibrutinib for chronic lymphocytic leukemia patients
4.
Enzalutamide vs Abiraterone: Which is Better for mCSPC?
5.
A study has developed molecular markers that predict meningioma recurrence.
1.
Innovative Strategies in Prostate Cancer Management: From Surveillance to Systemic Therapies
2.
Emerging Therapies Through Artificial Bone Marrow Niche Engineering
3.
Breast Cancer Secrets: AI-Powered Precision Medicine
4.
Revolutionizing Cancer Treatment: How Adoptive Cell Therapy is Overcoming Tumor Immune Evasion
5.
Environmental Carcinogen Exposure Risk Modeling: Current Evidence and Clinical Implications
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
1.
Current Scenario of Blood Cancer- Further Discussion on Genomic Testing & Advancement in Diagnosis and Treatment
2.
Navigating the Complexities of Ph Negative ALL - Part IV
3.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
4.
An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Q & A Session
5.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part I
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge